Africa Ebola outbreak: The rapidly spreading Bundibugyo strain of Ebola in Africa has raised global concerns. As a result, the Serum Institute is developing a new vaccine.

Africa Ebola crisis

Africa Ebola outbreak: Africa is once again facing a major threat from the Ebola virus. This time, the cause of concern is the Bundibugyo strain of Ebola, for which there is no approved vaccine yet. The rapidly increasing number of cases in the Democratic Republic of the Congo (DRC) and Uganda has alerted health agencies worldwide. According to reports, hundreds of suspected cases have been reported, and several people have died. The biggest concern is that the virus is now reaching densely populated areas, increasing the risk of spread to other countries.

The World Health Organization (WHO) and the Africa CDC have declared this situation a serious public health emergency. It is unclear how effective the existing vaccine for the Jerre strain of Ebola will be against the Bundibugyo strain. Therefore, the world is now racing to develop a new vaccine.

India plays a major role in the race to develop the vaccine.

In this difficult time, India's leading vaccine company, Serum Institute of India, is poised to play a crucial role. The Pune-based company is collaborating with Oxford University and CEPI to develop a new vaccine. This vaccine will be based on the ChAdOx platform, which was also used in the Covishield vaccine for COVID-19. Serum Institute states that it already possesses the technology and machinery needed to produce vaccine doses in a very short time.

According to the company, if everything goes well, initial production could begin within 20 to 30 days. Just as India provided large quantities of vaccines to the world during the COVID pandemic, it can now serve as a reliable partner in the Ebola crisis. This also demonstrates India's medical and biotech strengths.